|
Press Releases |
|
|
|
Tuesday, December 26, 2017 |
|
Nanobiotix: 2017 review and 2018 expected milestones |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
Monday, November 13, 2017 |
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
Friday, November 10, 2017 |
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
Monday, October 23, 2017 |
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
Friday, September 29, 2017 |
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
Friday, September 1, 2017 |
|
Nanobiotix half year results for the six months ended 30 June 2017 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
Friday, June 16, 2017 |
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
Tuesday, June 6, 2017 |
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
Thursday, May 18, 2017 |
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Paltalk to Host First Quarter 2024 Earnings Results Conference Call on Thursday, May 9, 2024 at 9:00 a.m. ET
May 2, 2024 00:28 HKT/SGT
|
|
|
PodcastOne (Nasdaq: PODC) Acquires Exclusive Sales and Distribution Rights to Dumb Gay Podcast
May 2, 2024 00:19 HKT/SGT
|
|
|
Forian Inc. to Announce First Quarter 2024 Results on May 14, 2024
May 2, 2024 00:09 HKT/SGT
|
|
|
Vietnam to Rethink Financial Services After a Cutting-edge Show at WFIS
May 1, 2024 16:42: JST
|
|
|
Vietnam to Rethink Financial Services After a Cutting-edge Show at WFIS
May 1, 2024 15:42 HKT/SGT
|
|
|
国美金融科技发布2023年度报告 商业保理稳中向好 多元化协同发展
May 1, 2024 13:18 HKT/SGT
|
|
|
國美金融科技發佈2023年度報告 商業保理穩中向好 多元化協同發展
May 1, 2024 13:12 HKT/SGT
|
|
|
Anson Resources Signs Lithium Supply Agreement with LG Energy Solution
May 1, 2024 09:00 HKT/SGT
|
|
|
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
Apr 30, 2024 19:40 HKT/SGT
|
|
|
Q2 Metals Announces Completion of Drill-Core Re-Evaluation for the Cisco Lithium Property, James Bay Territory, Quebec, Canada
Apr 30, 2024 19:09 HKT/SGT
|
|
|
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
|
|
|
Hong Kong Gifts, printing and packaging, and licensing events foster cross-industry opportunities
Apr 30, 2024 18:00 HKT/SGT
|
|
|
Moolec Announces New Patent Granting in the United States for Molecular Farming Platform
Apr 30, 2024 18:00 HKT/SGT
|
|
|
DCCI fortifies stance for Malaysia's greatest show: Wins support from key government organisations
Apr 30, 2024 17:56 HKT/SGT
|
|
|
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Apr 30, 2024 18:00 JST
|
|
|
|
More News >> |
|
|
|
|
|